NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:20PM ET
4.20
Dollar change
-0.14
Percentage change
-3.23
%
Index- P/E- EPS (ttm)-0.63 Insider Own5.17% Shs Outstand355.19M Perf Week-0.47%
Market Cap1.49B Forward P/E- EPS next Y-0.08 Insider Trans0.00% Shs Float336.82M Perf Month4.22%
Enterprise Value1.61B PEG- EPS next Q-0.05 Inst Own1.27% Short Float0.23% Perf Quarter30.03%
Income-222.53M P/S1.76 EPS this Y56.73% Inst Trans17.06% Short Ratio5.72 Perf Half Y-3.23%
Sales845.62M P/B1.51 EPS next Y71.08% ROA-9.92% Short Interest0.79M Perf YTD0.96%
Book/sh2.77 P/C3.72 EPS next 5Y- ROE-20.41% 52W High5.64 -25.54% Perf Year-13.58%
Cash/sh1.13 P/FCF- EPS past 3/5Y- - ROIC-15.49% 52W Low2.84 47.89% Perf 3Y-66.96%
Dividend Est.- EV/EBITDA- Sales past 3/5Y5.68% 11.52% Gross Margin16.71% Volatility3.16% 2.72% Perf 5Y-67.72%
Dividend TTM- EV/Sales1.90 EPS Y/Y TTM-125.61% Oper. Margin-16.29% ATR (14)0.17 Perf 10Y172.29%
Dividend Ex-DateJan 11, 2019 Quick Ratio1.93 Sales Y/Y TTM0.45% Profit Margin-26.32% RSI (14)52.87 Recom1.89
Dividend Gr. 3/5Y- - Current Ratio2.03 EPS Q/Q-47.87% SMA201.76% Beta1.67 Target Price6.11
Payout- Debt/Eq0.52 Sales Q/Q-7.09% SMA501.79% Rel Volume0.45 Prev Close4.34
Employees4827 LT Debt/Eq0.46 EarningsMay 06 BMO SMA2003.95% Avg Volume137.29K Price4.20
IPOFeb 05, 2004 Option/ShortNo / Yes EPS/Sales Surpr.-124.89% -7.68% Trades Volume61,993 Change-3.23%
Date Action Analyst Rating Change Price Target Change
Apr-24-25Upgrade Deutsche Bank Sell → Hold
Oct-07-24Downgrade Jefferies Buy → Hold
Aug-08-24Downgrade Deutsche Bank Hold → Sell
Jul-29-24Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $6
Jul-11-24Downgrade Deutsche Bank Buy → Hold
Apr-12-24Upgrade Deutsche Bank Hold → Buy
Jan-18-24Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-23-23Upgrade Morgan Stanley Equal-Weight → Overweight $12 → $16
Jun-16-23Downgrade BofA Securities Buy → Neutral $13
Jun-08-23Upgrade Citigroup Neutral → Buy
Jul-02-25 07:42PM
Jun-25-25 01:50AM
Jun-20-25 07:19PM
Jun-11-25 08:30PM
Jun-03-25 05:28PM
08:31PM Loading…
May-29-25 08:31PM
May-23-25 07:31PM
May-15-25 08:26PM
May-09-25 08:42PM
May-08-25 08:43PM
May-07-25 01:50AM
01:43AM
May-06-25 01:20AM
Apr-29-25 04:30AM
Apr-28-25 07:25PM
01:50AM Loading…
Apr-24-25 01:50AM
Apr-17-25 03:58PM
02:24PM
01:45AM
Apr-10-25 06:00AM
Apr-02-25 03:30PM
Mar-06-25 07:55PM
Mar-04-25 01:45AM
Feb-26-25 02:00AM
Jan-22-25 02:00AM
Dec-11-24 02:00AM
Nov-29-24 02:00AM
Nov-24-24 05:49PM
Nov-22-24 11:15AM
08:35AM
12:14AM Loading…
Nov-20-24 12:14AM
Nov-19-24 06:01PM
Nov-18-24 07:47PM
07:00AM
Nov-15-24 10:45PM
03:43PM
Nov-14-24 05:30PM
04:15PM
Nov-07-24 08:37AM
Nov-06-24 01:20AM
Nov-05-24 01:50AM
Nov-04-24 07:18PM
Oct-30-24 03:30AM
Oct-23-24 02:00AM
Sep-26-24 02:00AM
Sep-20-24 09:45AM
Sep-05-24 08:00AM
Sep-03-24 01:50AM
Aug-14-24 10:09PM
01:30AM
Aug-13-24 02:00AM
Aug-09-24 10:24AM
Aug-08-24 01:50AM
Aug-07-24 07:15AM
Aug-06-24 07:29PM
03:30PM
03:15PM
Jul-10-24 01:50AM
Jul-08-24 08:20AM
Jun-28-24 08:47PM
Jun-25-24 01:50AM
Jun-17-24 07:52PM
Jun-12-24 01:50AM
Jun-10-24 12:15PM
May-30-24 02:00AM
May-29-24 11:46AM
May-28-24 01:50AM
May-24-24 11:15PM
May-23-24 11:07AM
May-22-24 06:52AM
01:30AM
May-15-24 06:20AM
May-14-24 08:30AM
May-02-24 09:00AM
Apr-30-24 02:50AM
Apr-26-24 09:56AM
Apr-24-24 11:13PM
01:20AM
01:08AM
Apr-23-24 03:00PM
Apr-18-24 07:45AM
Apr-17-24 09:15AM
01:50AM
01:50AM
Apr-12-24 10:55AM
Mar-06-24 01:50AM
Feb-07-24 02:00AM
Jan-22-24 02:00AM
Jan-10-24 09:45AM
Jan-08-24 01:50AM
Jan-04-24 01:45AM
Jan-03-24 12:45PM
Dec-19-23 02:00AM
Dec-14-23 02:00AM
Dec-11-23 02:00AM
Dec-06-23 01:50AM
Nov-15-23 01:50AM
Nov-08-23 01:20AM
Nov-07-23 01:50AM
01:30AM
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.